Contact us Find us Register
Back to previous section

Citi hikes Hikma price target, cites ‘healthy trends’ for injectables and US Generics.

Citi lifted its price target on Hikma Pharmaceuticals on Tuesday to 2,845p from 2,770p as it said IQVIA April data highlighted "healthy trends" for injectables and US Generics.

  • Hikma Pharmaceuticals
  • 11 June 2024 09:30:13
Hikma Pharmaceuticals

Source: Sharecast

"The strategy at US Generics (30/20% of sales/EBIT) longer-term remains reducing volatility and delivering a sustainable EBIT of $100-120m, as a result of efforts to increase contract manufacturing activities and further broadening the Specialty portfolio," it said.

"More importantly, we argue investors should focus on long-standing efforts to improve the product mix at Branded (24/22% 2024e sales/EBIT) finally paying dividends, resulting in a sustainable step-up in profitability.

"Lastly, Injectables continues to offer high single-digit growth prospects at attractive margins, with greenfield efforts to develop a US compounding business expected to break even in 2025."

Citi said it assumes $350m sales and 35% EBIT margin in 2035.

The bank said it was moving to the top end of guidance on stronger profitability at Branded/Injectables.

At 0930 BST, Hikma shares were up 2.8% at 1,983.44p.

FTSE 100 ( UKX )

ISIN: N/A
Exchange: London Stock Exchange
Sell:
0.00
Buy:
0.00
Change: 46.12 ( 0.55 %)
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.